CRISPR gene editing can cause hundreds of unintended mutations – Phys.Org

May 29, 2017 CRISPR-associated protein Cas9 (white) from Staphylococcus aureus based on Protein Database ID 5AXW. Credit: Thomas Splettstoesser (Wikipedia, CC BY-SA 4.0)

As CRISPR-Cas9 starts to move into clinical trials, a new study published in Nature Methods has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome.

"We feel it's critical that the scientific community consider the potential hazards of all off-target mutations caused by CRISPR, including single nucleotide mutations and mutations in non-coding regions of the genome," says co-author Stephen Tsang, MD, PhD, the Laszlo T. Bito Associate Professor of Ophthalmology and associate professor of pathology and cell biology at Columbia University Medical Center and in Columbia's Institute of Genomic Medicine and the Institute of Human Nutrition.

CRISPR-Cas9 editing technologyby virtue of its speed and unprecedented precisionhas been a boon for scientists trying to understand the role of genes in disease. The technique has also raised hope for more powerful gene therapies that can delete or repair flawed genes, not just add new genes.

The first clinical trial to deploy CRISPR is now underway in China, and a U.S. trial is slated to start next year. But even though CRISPR can precisely target specific stretches of DNA, it sometimes hits other parts of the genome. Most studies that search for these off-target mutations use computer algorithms to identify areas most likely to be affected and then examine those areas for deletions and insertions.

"These predictive algorithms seem to do a good job when CRISPR is performed in cells or tissues in a dish, but whole genome sequencing has not been employed to look for all off-target effects in living animals," says co-author Alexander Bassuk, MD, PhD, professor of pediatrics at the University of Iowa.

In the new study, the researchers sequenced the entire genome of mice that had undergone CRISPR gene editing in the team's previous study and looked for all mutations, including those that only altered a single nucleotide.

The researchers determined that CRISPR had successfully corrected a gene that causes blindness, but Kellie Schaefer, a PhD student in the lab of Vinit Mahajan, MD, PhD, associate professor of ophthalmology at Stanford University, and co-author of the study, found that the genomes of two independent gene therapy recipients had sustained more than 1,500 single-nucleotide mutations and more than 100 larger deletions and insertions. None of these DNA mutations were predicted by computer algorithms that are widely used by researchers to look for off-target effects.

"Researchers who aren't using whole genome sequencing to find off-target effects may be missing potentially important mutations," Dr. Tsang says. "Even a single nucleotide change can have a huge impact."

Dr. Bassuk says the researchers didn't notice anything obviously wrong with their animals. "We're still upbeat about CRISPR," says Dr. Mahajan. "We're physicians, and we know that every new therapy has some potential side effectsbut we need to be aware of what they are."

Researchers are currently working to improve the components of the CRISPR systemits gene-cutting enzyme and the RNA that guides the enzyme to the right geneto increase the efficiency of editing.

"We hope our findings will encourage others to use whole-genome sequencing as a method to determine all the off-target effects of their CRISPR techniques and study different versions for the safest, most accurate editing," Dr. Tsang says.

The paper is titled, "Unexpected mutations after CRISPR-Cas9 editing in vivo." Additional authors are Kellie A. Schafer (Stanford University), Wen-Hsuan Wu (Columbia University Medical Center), and Diana G. Colgan (Iowa).

Explore further: Accurate DNA misspelling correction method

More information: Unexpected mutations after CRISPR-Cas9 editing in vivo, Nature Methods (2017).

Researchers at the Institute of Basic Science (IBS) proved the accuracy of a recently developed gene editing method. This works as "DNA scissors" designed to identify and substitute just one nucleotide among the 3 billion. ...

A team from the Center for Genome Engineering, within the Institute for Basic Research (IBS), succeeded in editing two genes that contribute to the fat contents of soybean oil using the new CRISPR-Cpf1 technology: an alternative ...

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, ...

The IBS research team (Center for Genome Engineering) has successfully confirmed that CRISPR-Cas9 has accurate on-target effects in human cells, through joint research with the Seoul National University College of Medicine ...

A team of researchers at Western University is playing with molecular-Lego by adding an engineered enzyme to the revolutionary new gene-editing tool, CRISPR/Cas9. Their study, published today in the Proceedings of the National ...

Using the new gene-editing enzyme CRISPR-Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.

An ancient sea creature, discovered off the coast of Scotland in 2011, has shed new light on how evolution formed the modern brain.

Faceless fish and other weird and wonderful creatures, many of them new species, have been hauled up from the deep waters off Australia during a scientific voyage studying parts of the ocean never explored before.

Biologists have always been fascinated by the diversity and changeability of life on Earth and have attempted to answer a fundamental question: How do new species originate?

With prices down and weather patterns unpredictable, these are tough times for America's cotton farmers, but new research led by Z. Jeffrey Chen at The University of Texas at Austin might offer a break for the industry. He ...

From Charles Darwin's famous finches to a new study that takes a rare look at a common order of birdswaterfowlevolution has a tendency to reveals itself through bird beaks.

Researchers have identified key genes associated with flowering time in the pigeon pea, a finding that could lead to more productive plants for this important source of protein.

Adjust slider to filter visible comments by rank

Display comments: newest first

If a person has 3 months to live and they use crispr/cas9 to cure the cancer, and it works, what is the worst than can happen to him?

I'm not a biologist, so no idea how conceivable or absurd that idea might be. But then there's the whole thing with the Tasmanian devils. Anyway, you asked about worst cases, and that is one possible thing that people who are against this might be thinking.

Open a door, find 12 new doors. Like the knowledge that carbon nanos caused cancer but the powers-that-be decided we should use it any way because it was so convenient.

We are so screwed! This is worse than the advent of nuclear weapons.

this might cause regulated interests to think twice before deploying this for profit. It will not help us at all against weaponized CRISPR, though...

Crispr is the only way the human race will survive. Without it the machines rule. With crispr the human race increases everyone's IQ 10 fold. The vary smartest of us say "be very afraid of AI". Musk likened AI to a devil in a bottle. It's the 2nd level of our most brilliant people that can't see the danger AI poses. Raise everyone's IQ by 10X and we will make much better decisions and solve the current world's problems overnight.

Meatbrains are passe which is why we are so intent on replacing them.

Watch Forbidden Planet to see what happens when you mix intelligence with the need to survive to procreate.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the rest here:
CRISPR gene editing can cause hundreds of unintended mutations - Phys.Org

Researchers make breakthrough discovery in fight against bowel cancer – Medical Xpress

May 31, 2017 Professor Mark Lawler, Queen's University Belfast. Credit: Queen's University Belfast

New research led by Queen's University Belfast has discovered how a genomic approach to understanding bowel (colorectal) cancer could improve the prognosis and quality of life for patients.

For clinicians, treating patients with bowel cancer can be particularly challenging. Professor Mark Lawler, Chair in Translational Genomics, Centre for Cancer Research and Cell Biology at Queen's and joint Senior Author on the study explains: "Currently patients with colorectal cancer are offered chemotherapy treatment. While this treatment may be successful for some patients, for others it will have no effect on fighting the cancer, though the patients may suffer debilitating side effects such as nerve damage that can result in a loss of sensation or movement in a part of the body. A 'one size fits all' approach isn't a viable option if we are to effectively tackle this disease."

Researchers at Queen's, in collaboration with the University of Oxford and the University of Leeds have made a significant advance in the treatment of bowel cancer. The study, which has been published in the high impact journal Nature Communications, has shown how defining precise gene signatures within bowel cancer cells can allow us to develop novel prognostic and predictive markers for bowel cancer and help to drive personalised medicine approaches.

Dr Philip Dunne, Senior Research Fellow at Queen's said: "Through analysing the molecular and genetic data generated from patient tissue samples, we have discovered that there are different subtypes of bowel cancer. This research unequivocally identifies robust gene signatures that can be used to inform patient management. It will allow us to identify particular gene signatures that indicate sensitivity or resistance to specific therapies. Thus, we can tailor treatment to the individual patient, maximising its effectiveness while minimising potential side effects."

Dr Catherine Pickworth, science information officer at Cancer Research UK, a funder of the study, added: "Personalised medicine aims to give the best treatment to each patient, sparing people unnecessary therapy if it won't help.

"This study is a step forward in achieving this, giving us genetic signatures to look out for in bowel cancer patients. The next steps will be to find out which treatment works best for each genetic signatures so that cancer treatments can be tailored to each patient, so they have the best chance of beating cancer."

Bowel cancer is the fourth most common cancer in the UK, with 41,200 people newly diagnosed each year. A number of treatment options are available but mortality rates remain high, with bowel cancer the second most common cause of cancer death in the UK.

This research was performed as part of Stratified Medicine in Colorectal Cancer (S:CORT), an MRC-Cancer Research UK funded stratified medicine consortium, bringing together the best of UK science and clinical care in bowel cancer to develop personalised medicine treatment approaches in this common malignancy.

S:CORT involves key partnerships with patients and patient advocacy groups. Ed Goodall, a survivor of bowel cancer and a member of S:CORT explains: "In the past, a tumour was a tumour. Patients are offered chemotherapy and this may not be effective or necessary depending on the patient yet they will still endure all the horrors this treatment can cause including nausea and hair loss.

"If the oncologist knows more about the subtype of bowel cancer, they will know whether the treatment will be necessary or effective. From a patient point of view, discovering the subtypes of this cancer is really ground breaking work because it will have massive implications for patient care and treatment."

Professor Tim Maughan, Professor of Clinical Oncology at the University of Oxford and Principal Lead of the S:CORT Consortium said: "This research emphasises how a collaborative approach can give significant insight into bowel cancer disease biology, but also to begin to translate this knowledge into clinically-relevant applications. As part of the work of the S:CORT consortium, we will now focus on making sure that the research is put into practice so that it can become part of the standard of care for patients."

Deborah Alsina MBE, Chief Executive of Bowel Cancer UK, the UK's leading bowel cancer research charity and a partner in S:CORT said: "This important study highlights how increasing our understanding of what makes normal cells go wrong is key to developing new approaches that can improve outcomes for patients. With nearly 16,000 people dying from bowel cancer each year, it is essential that we increase our understanding of what drives the disease and then improve and extend the range of treatment options available. The results of this study take us a step closer to achieving this."

Explore further: Researcher finds key to drug resistant bowel cancer

More information: Nature Communications (2017). DOI: 10.1038/NCOMMS15657

Blocking a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

A new test could help patients with advanced bowel cancer get the best treatment for their disease, according to a Cancer Research UK clinical trial published today in JAMA Oncology.

A new study that combines genetic information on bowel cancer with NHS patient outcome data has found a link between family history of the disease and a better chance of survival, published in the British Journal of Cancer.

Researchers at Queen's University have made a significant breakthrough that may benefit patients with bowel cancer.

Manchester researchers have provided early evidence to suggest that a blood test could be used to identify bowel cancer patients that may benefit from more intensive chemotherapy.

Up to a quarter of patients with bowel cancer who have a family history of the disease could have the causes of their cancer identified through gene testing, a new study reports.

New research led by Queen's University Belfast has discovered how a genomic approach to understanding bowel (colorectal) cancer could improve the prognosis and quality of life for patients.

Batman and Robin. Sherlock Holmes and Dr. Watson. Fiction is full of dynamic duos that work together to accomplish amazing feats. When one partner is out of commission, the other steps in to make sure the job gets done. But ...

Research in the field of kidney cancer, also called renal cancer, is vital, because many patients with this disease still cannot be cured today. Researchers from the University of Zurich have now identified some of the gene ...

A University of Otago, Christchurch, discovery of missing DNA in women who develop breast cancer at a young age could hold the key to helping them beat the disease.

Ashkenazi Jewish women are known to have a predisposition to the inherited breast cancers BRCA1 and BRCA2, but currently genetic testing in this group is limited to women affected by breast and ovarian cancers and those who ...

In a new study, scientists at The University of Texas at Dallas have found that some types of cancers have more of a sweet tooth than others.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Link:
Researchers make breakthrough discovery in fight against bowel cancer - Medical Xpress

Miami Dolphins safeties Reshad Jones, Nate Allen aim for ‘beautiful thing’ called chemistry – Palm Beach Post (blog)

Dolphins S Reshad Jones played only six games before injuring his shoulder last season. (Allen Eyestone/The Post)

DAVIE The chemistry with fellow safety Reshad Jones isnt what it needs to be, but its coming along, Nate Allen was saying. There was no panic in his voice because, after all, this is only May.

This is what OTAs are for, said Allen, who joined the Dolphins in free agency from Oakland.

Only a few minutes earlier Tuesday, Jones addressed the media and was equally calm about one of the more pressing matters concerning the Dolphins defense, but for one other reason: He has been through this before.

If its the offseason, theres a good chance the Dolphins are sorting out wholl be lining up alongside Jones at safety. Except for a brief spell of continuity with Chris Clemons early in his career, Jones has been on an endless quest to develop chemistry with safeties ranging from Louis Delmas to Jimmy Wilson to Michael Thomas, to name a few.

I know I had a lot, Jones said. But I didnt know it was eight.

Dolphins safety Nate Allen listens to a question during a news conference during OTAs on Tuesday. (AP Photo/Wilfredo Lee)

Injuries have played a huge role, wiping out both Jones and Isa Abdul-Quddus last year and ending Abdul-Quddus career.

That left an opening. In stepped Allen, who was taken 126 spots earlier than Jones in the 2010 draft, which is a blessing of sorts for the Dolphins. Playing the same position and having entered the league at the same time, theyve kept tabs on one another from afar.

We came out together, so I kind of knew him, Jones said. He knows ball.

Allen also knows Jones.

His play speaks for itself, Allen said. Hes who he is for a reason and hes the guy. He makes a lot of plays. Hes just a great playmaker. I could see it early and Ive watched him through the years. As Ive been in other places, Ive always watched him on tape. He stands out.

Jones made the Pro Bowl in 2015 and stood a good chance of repeating last season before a shoulder injury ended his season. From the sidelines, he watched his team qualify for the playoffs for the first time since he arrived.

It was kind of brutal for me, but I was happy for my guys, he said.

Having recently gained full medical clearance, Jones is confident hell regain top form.

I always felt like I was one of the best safeties in the league and I still feel that way, Jones said. Numbers dont lie. My numbers are top of the line of all of them.

Allen, who signed a one-year, $3.4 million deal, also believes hes 100 percent after suffering an MCL injury early in 2015 and serving as a backup with the Raiders last season. Allen said he feels comfortable, whether its at strong safety or free safety, in coverage or run support. Its largely a matter of developing an understanding with Jones.

I think were making good progress, Allen said. And its not just me and Reshad. Its the entire DB group. This is the first time Ive played with these guys and the first time a lot of us have played together, so everybodys just kind of feeling each other out.

Because once you get that chemistry in the back end, you can make it a beautiful thing.

The question is, how long will this tandem last? The Dolphins also added safety T.J. McDonald from the Rams, but hell miss the first half of the season for violating the leagues substance abuse policy.

I think we can be special, Jones said. Weve got the ball rolling in the right direction. We just have to continue to put the work in and make it happen.

Miami Dolphins Xavien Howard: I was never 100 percent healthy lastseason

Miami Dolphins QB Ryan Tannehill (knee) declares himself 100percent

Miami Dolphins Byron Maxwell: mentoring Cordrea Tankersley myjob

Miami Dolphins Ndamukong Suh sick and tired of not winning playoffgames

10 Miami Dolphins under pressure thisoffseason

Previous

Dolphins S Reshad Jones calls recent injury biggest challenge ofcareer

View post:
Miami Dolphins safeties Reshad Jones, Nate Allen aim for 'beautiful thing' called chemistry - Palm Beach Post (blog)

Public donations sought for career returners’ chemistry fellowship – Chemistry World (subscription)

The University of Oxford is asking the public for donations to support a new chemistry fellowship that will be awarded to someone returning to research after a career break.

The Dorothy Hodgkin fellowship named after the x-ray crystallographer and chemistry Nobel laureate who was the first woman at the university to receive maternity pay aims to help address the leaky pipeline of women leaving academia. The initial goal is to fund a five-year research post in the universitys chemistry department as well as a stipendiary lecturer to cover teaching.

The crowdfunding campaign is a joint enterprise between the universitys chemistry department and Somerville College, where Hodgkin was a fellow.

So far it has raised more than 162,000 of the 500,000 target. When the total reaches 196,500 it will be matched by a group of four anonymous donors. Eventually, the project hopes to raise enough money to ensure a continuous stream of fellows returning to chemistry.

More here:
Public donations sought for career returners' chemistry fellowship - Chemistry World (subscription)

Royal Bank of Canada Boosts Puma Biotechnology Inc (PBYI) Price Target to $60.00 – The Cerbat Gem


Chaffey Breeze
Royal Bank of Canada Boosts Puma Biotechnology Inc (PBYI) Price Target to $60.00
The Cerbat Gem
Puma Biotechnology Inc logo Puma Biotechnology Inc (NYSE:PBYI) had its price objective lifted by Royal Bank of Canada from $40.00 to $60.00 in a report published on Thursday. The brokerage currently has a sector perform rating on the biopharmaceutical ...
Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst's PredictionsStockNewsJournal
Puma Biotechnology Inc (PBYI) Breaks into New 52-Week High on May 30 SessionEquities.com
Puma Biotechnology, Inc. (PBYI): A Detailed Look at its Institutional OwnershipPost Analyst
Chaffey Breeze -MoneyMakingArticles -Market Exclusive -SEC.gov
all 62 news articles »

Original post:
Royal Bank of Canada Boosts Puma Biotechnology Inc (PBYI) Price Target to $60.00 - The Cerbat Gem

Form 8-K PUMA BIOTECHNOLOGY, INC. For: May 24 – StreetInsider.com

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May30, 2017 (May 24, 2017)

PUMA BIOTECHNOLOGY, INC.

(Exact Name of Registrant as Specified in its Charter)

10880 Wilshire Boulevard, Suite 2150

Los Angeles, California 90024

(Address of principal executive offices) (Zip Code)

(424) 248-6500

(Registrants telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

On May24, 2017, Puma Biotechnology, Inc. (the Company) announced that the U.S. Food and Drug Administrations (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 4 to recommend approval of PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer based on finding that the risk-benefit profile of neratinib is favorable. Neratinib is an investigational therapy for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen.

ODAC is an independent panel of experts that evaluates data concerning the efficacy and safety of marketed and investigational products for use in the treatment of cancer and makes appropriate recommendations to the FDA. Although the FDA will consider the recommendation of the panel, the final decision regarding the approval of the product is made by the FDA solely, and the recommendations by the panel are non-binding.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Alan H. Auerbach

See the original post:
Form 8-K PUMA BIOTECHNOLOGY, INC. For: May 24 - StreetInsider.com

Peek into your genes: NASA one-year mission investigators identify links to vision problems – Phys.Org

May 31, 2017 by Amy Blanchett Astronaut Scott Kelly opens a bag of assorted fruit (oranges, lemons, grapefruits) in the Node 2 module after being unpacked from the Kounotori H-II Transfer Vehicle 5 (HTV-5). Astronauts are pleased to discover fresh fruit and vegetables in cargo shipments to the International Space Station because sometimes due to delivery schedules, weight factors and accessibility of refrigeration on the station these type of foods are not always readily available. It is important for astronauts to consume vitamins and minerals in space to maintain their health. Credit: NASA

Healthy Vision Month, NASA's One-Year Mission investigators are peering into their new findings to help address astronaut vision issues. While the One-Year Mission has concluded for retired astronaut Scott Kelly, NASA's Human Research Program is focusing on comparing previous six-month mission findings to One-Year Mission preliminary findings.

Nutritional Biochemistry Lab lead Scott M. Smith, Ph.D., takes a broad look at biochemistry. He studies the astronaut diets along with protein, vitamin, mineral, and other chemicals in blood and urine to look for indicators of disease or other physiological changes. His team discovered that astronauts with vision issues had biochemical differences before ever leaving Earth as compared to astronauts without vision issues, and subsequently documented that this was evidence of a genetic predisposition for some astronauts to develop vision and eye issues. He thinks his team is on the path to help resolve vision issues for astronauts. This is an important finding as NASA prepares for a human journey to Mars.

Typically, physiologists and scientists study one system at a time, but nutrition is a cross-cutting science with impacts across systems biology. Smith emphasizes the importance of studying the human body holistically, which is why his team has led the effort to create a biochemical database making it more efficient to interface with other researchers, such as the 22 other One-Year Mission investigators.

Another investigator who works with Smith at NASA's Johnson Space Center is Michael Stenger, Ph.D. He is the Cardiovascular and Vision Lab lead and principal investigator for the Fluid Shifts investigation, which is an international experiment designed to determine the relationship between headward fluid shifts and ocular structural changes. Spaceflight Associated Neuro-ocular Syndrome, or SANS, is hypothesized to be caused by blood flow toward the head due to lack of gravity, resulting in changes to eye structure and possibly vision changes. This headward fluid shift may be responsible for vision changes, flattening of the eyeball and swelling of some tissues in the back of the eye and engorgement of the optic nerve sheath seen in approximately one out of three International Space Station astronauts.

The One-Year Mission was a great opportunity to see if vision changes occurring during six-month missions continued and worsened when the mission is extended to a year. Stenger could also see if astronauts who did not have vision issues at the six-month mark, developed them when extended to one year in space. The preliminary findings are a bit of both. One subject developed SANS early in the mission and had some symptoms worsen as the mission lengthened while another did not. The subject who did not experience SANS symptoms during the first six months of flight did start to show some changes near the end of his year in space, suggesting that length of time in space may impact the eye.

The video will load shortly

Both Smith and Stenger are working together to solve eye and vision problems for astronauts. They agree their investigations are just scratching the surface and there is a lot of work that still needs to be done on the ground and in space to validate theories. While Scott Kelly returned to Earth in a healthy state, NASA continues to keep its vision focused on sending humans safely and effectively on a three-year journey to Mars.

Explore further: The 'eyes' have it: Astronaut vision and ophthalmologic problems explained

More information: Sara R. Zwart et al, Astronaut ophthalmic syndrome, The FASEB Journal (2017). DOI: 10.1096/fj.201700294

Journal reference: FASEB Journal

Provided by: NASA

Just when you think you've seen it all, our eyes look to be victims of a low-gravity environments, too. According to new research published in the January 2016 issue of The FASEB Journal, two significant genetic differences ...

Many astronauts who come back from space experience poorer vision after flight, some even years after, and researchers at the University of Alabama at Birmingham are working to see why.

Astronauts may experience blurry vision and impaired eyesight after long spaceflights due to changes in spinal fluid that occur while in microgravity, researchers said Monday.

Centuries ago, ships often sailed with crews numbering in the hundreds returning with tens. Cause of death: Scurvy - a severe depletion of Vitamin C. Today's explorers cross miles of space with no hope of finding an island ...

NASA needs to get cracking if it wants to keep its astronauts alive and well on missions to Mars, according to an in-house report issued Thursday.

In a US presidential election that's already been out of this world, the lone American astronaut in outer space has cast his vote, NASA said Monday.

Scientists have long tried to explain the origin of a mysterious, large and anomalously cold region of the sky. In 2015, they came close to figuring it out as a study showed it to be a "supervoid" in which the density of ...

The growing amount of fast-moving space debris orbiting the Earth could lead to catastrophic collisions with satellites, hurting economies, researchers warned Wednesday ahead of a summit to coordinate efforts to remove the ...

A giant gas planet up to fifty times the mass of Jupiter, encircled by a ring of dust is likely hurtling around a star more than a thousand light years away from Earth, according to new research by an international ...

Saturn's icy, ocean-bearing moon Enceladus may have tipped over in the distant past, according to recent research from NASA's Cassini mission. Researchers with the mission found evidence that the moon's spin axisthe line ...

NASA technologists produced telescope mirrors with the highest reflectance ever reported in the far-ultraviolet spectral range. Now, they're attempting to set another record.

Lighter-toned bedrock that surrounds fractures and comprises high concentrations of silicacalled "halos"has been found in Gale crater on Mars, indicating that the planet had liquid water much longer than previously ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See more here:
Peek into your genes: NASA one-year mission investigators identify links to vision problems - Phys.Org

Grey’s Anatomy Ellen Pompeo Hamptons House Tour – People – PEOPLE.com


PEOPLE.com
Grey's Anatomy Ellen Pompeo Hamptons House Tour - People
PEOPLE.com
Ellen Pompeo's operations are usually restricted to the OR on Grey's Anatomy. But the actress found herself performing a surgery of sorts on her modern barn ...
Ellen Pompeo's Hamptons House | POPSUGAR HomePOPSUGAR
Ellen Pompeo's Sag Harbor Home Is a Modern Take on a Classic BarnArchitectural Digest

all 3 news articles »

Read more from the original source:
Grey's Anatomy Ellen Pompeo Hamptons House Tour - People - PEOPLE.com

American Chemistry Council: Obstructing Formaldehyde Safeguards Then and Now – Union of Concerned Scientists (blog)

Photo: DeAntre Bryant/UCS

The chemical industry has once again staved off federal action that would protect public health, as the EPA announced last week that it would be delaying compliance dates for the long-awaited formaldehyde emission standards for composite wood productsstandards that were finalized in December 2016. This is the latest move brought to you by an industry with a long history of attacking science and an administration willing to do its bidding.

Its no surprise that industry employs tactics like manufacturing doubt, attacking scientists, and influencing policymakers in a calculated effort to delay or halt science-based safeguards. Under the Trump administration, we have already seen a host of important policies rooted in strong science rolled back or delayed, including stronger beryllium, silica, ozone, and methane standards, stream protection requirements for mining operations, vehicle fuel economy standards, coal plant wastewater standards, risk management program amendments, and mercury and air toxics standards.

Last week, The New York Times reported on the way in which Administrator Scott Pruitts EPA has loosened its regulatory grip on the business community, and especially the oil and gas industry with which Pruitt has longstanding financial ties. The President of the Western Energy Alliance, an association of oil and gas companies, told the NYT, We are so used to not being able to move an agenda forward that it has been very surprising how quickly things have changed.

But what does it mean for us when industry moves its agenda forwardespecially when that agenda involves stopping the creation of evidence-based limits for chemicals, proven unsafe, that will make their way into our homes or drinking water?

The binders used to glue together wood fibers in particleboard, plywood, and other building materials often contain formaldehyde. Photo: Rotor_DB/Creative Commons (Wikimedia).

Formaldehyde is a colorless, flammable chemical widely used in building materials, medicinal and personal care products, and furnishings. Fumes from these products can be harmful to human health, especially when they accumulate indoors at high concentrations. Acute exposure can lead to nausea, headaches, and eye, nose, throat and skin irritation, even asthma exacerbation. Chronic exposure has been linked to cancers in humans, including cancers of the nose and throat, lymphomas, and leukemia. In 2004, the International Agency for Research on Cancer concluded that formaldehyde is a human carcinogen, and the U.S. Department of Health and Human Services listed it is as a known human carcinogen in 2011.

Health impacts have been understood since the 1980s, and yet over thirty years later, there are no federal restrictions on formaldehyde emissions in the home. Without standards in place, public health is at risk. Back in 2005, the cheaply constructed emergency trailers that housed Hurricane Katrina refugees were found to have unsafe levels of formaldehyde, earning them the toxic trailers nickname, while inhabitants already dealing with displacement in the midst of an environmental disaster suffered from respiratory problems, burning eyes, and other ailments. Without controls on formaldehyde emissions, these trailers have been resold and some were even used as temporary housing for workers cleaning up the BP oil spill in the gulf in 2010. Wood products used to build and remodel homes across the country can still contain formaldehyde at potentially unsafe levels.

Then

The trade organization representing chemical companies including the makers of formaldehyde, the American Chemistry Council (ACC), worked to downplay the risks of the chemical and to delay and otherwise thwart the formaldehyde emissions rule as it was first being proposed and finalized by the EPA. The ACC created a website that touts the environmental benefits of formaldehyde, casts doubt on established health studies linking exposure to a range of ailments, and assures consumers that voluntary industry standards were strong enough to protect them. The ACC also persuaded Congress to commission the National Academies of Science to reevaluate EPA science on formaldehyde, resulting in a delay in the process lasting 3 years and reaching the same conclusion that formaldehyde should be listed as known to be a human carcinogen.

The ACC even got involved with White House-level review. In 2012, the White House Office of Management and Budget meeting record shows that it had at least five meetings with industry executives, their lobbyists, and ACC-financed lawmakers (like Senator Vitter), asking them to halt the EPA proposal, which apparently worked. After OMB-review, the EPA deleted from its cost-benefit analysis the benefits of reduced health ailments like asthma and fertility issues that a formaldehyde standard would have prevented, dropping the benefits from $278 million to $48 million annually.

Now

The formaldehyde emissions rule was issued by the EPA in December 2016, and the ACC has continued to deny the science used by the EPA and to lobby the EPA and Congress on the issue. The ACC spent nearly $1.5 million lobbying agencies and Congress on a host of issues in just the first quarter of 2017 (January to March), including on formaldehyde, hexavalent chromium, the nomination of EPA Administrator Scott Pruitt, EPAs Science Advisory Board, the HONEST Act, the Regulatory Accountability Act, Risk Management Program amendments, and even FY 2018 appropriations for the EPA.

Just this month, a study was issued that was funded by the Foundation for Chemistry Research and Initiatives (FCRI), a nonprofit organization established by the ACC. According to its financial filings the nonprofit works to address uncertainties and answer questions on health and environmental issues, taking on projects that will furnish crucial information, peer-reviewed scientific research, expert panels, and workshops to inform policy. FCRI granted a total of $425,294 of its revenue (which comes entirely from ACC)to study formaldehyde in 2012 and $425,114 to Environ International Corporation (now Ramboll Environ) and other consulting firms and research institutions to reevaluate formaldehyde data in 2014. Environ International has been called a hired gun by former OSHA administrator David Michaels, and the firm has been commissioned by several corporations to contribute to the scientific literature, including notorious tobacco company R.J. Reynolds (now Reynolds American Incorporated Services Company) and the Industrial Health Foundation (a former trade organization for industrial facilities), conducting studies with conclusions that downplayed the risks of menthol cigarettes and hexavalent chromium.

This FCRI issued grants led to several studies that helped to sow uncertainty about the potential of long-term exposure to formaldehyde to cause myeloid leukemia. A 2013 study by Environ authors funded by the FCRI and Momentive Special Chemicals Inc. (now Hexion Specialty Chemicals, Inc.), a formaldehyde-producing chemical company, used FOIA-obtained data to refute findings suggesting a link between formaldehyde exposure and leukemia. Earlier this month, the ACC touted another FCRI-funded study with the headline new study challenges formaldehyde cancer findings, after the study built upon its 2013 work and concluded that there was no causal association between formaldehyde and leukemia, of course not mentioning the very clear conflict of interest at hand. The ACC has used this study to urge the EPA not to characterize formaldehyde as linked to leukemia development.

For years now, no matter how strong the scientific consensus around an issue is, the ACC has continuously worked to obscure scientific findings and obstruct policies that are designed to protect public health and safety, all to save chemical companies time and money.

Photo: FEMA

For people like Becky Gillette, this rules enforcement cannot come soon enough. She told the New York Times, People think
that just because Congress passed the legislation five years ago, the problem has been fixed, said Becky Gillette, a Mississippi resident affected by Hurricane Katrina who was one of the first people to notice that the FEMA trailers were causing health problems. Real peoples faces and names come up in front of me when I think of the thousands of people who could get sick if this rule is not done right.

The EPAs final formaldehyde emissions rule estimates that 132 million individuals will be living in housing units where composite wood products have been installed within the past 11 years. Considering that population, the implementation of this rule will help prevent 26 to 64 nasopharyngeal cancer cases and 92,218 to 604,155 cases of eye irritation annually. These counts dont even take into consideration other health ailments and types of cancer. A delay of just three months in implementation could mean the difference between cancer diagnoses and clean bills of health for at least eight Americans with faces and names.

Theres still a chance to tell EPA to leave the compliance dates alone and move forward with the rule. The EPA is accepting comments on its decision until June 8.

For more on the American Chemistry Councils history of fighting policies that regulate chemicals produced by its member companies (think BPA, silica, and flame retardants), even when scientific evidence points to adverse health or environmental impacts, check out our 2015 report Bad Chemistry: How the Chemical Industrys Trade Association Undermines the Policies that Protect Us.

Posted in: Science and Democracy Tags: American Chemistry Council, Conflict of Interest, formaldehyde

Support from UCS members make work like this possible. Will you join us? Help UCS advance independent science for a healthy environment and a safer world.

Continued here:
American Chemistry Council: Obstructing Formaldehyde Safeguards Then and Now - Union of Concerned Scientists (blog)

TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the … – PR Newswire (press release)

TAIPEI, Taiwan, May 30, 2017 /PRNewswire/ --TaiGen Biotechnology Company, Limited ("TaiGen") today announced that it has submitted a New Drug Application (NDA) for the intravenous formulation of Taigexyn (Nemonoxacin) to the China Food and Drug Administration (CFDA). Taigexyn is a novel non-fluorinated quinolone antibiotic.The NDA submission is supported by a pivotal Phase 3 trial comparing intravenous formulations of Taigexyn 500 mg to levofloxacin 500 mg in 518 patients with moderate to severe community-acquired pneumonia. The clinical success rates were 91.8% for Taigexyn vs. 85.7% for levofloxacin and Taigexyn was shown to be non-inferior to levofloxacin meeting the primary endpoint of the pivotal trial.

About Taigexyn Taigexyn is a novel broad spectrum antibiotic with excellent efficacy against drug-resistant bacteria available in both oral and intravenous formulations. The oral formulation is already approved for marketing and launched in Taiwan and mainland China. In addition, Taigexyn is also partnered in Russia, Commonwealth Independent States, Turkey, Mexico, Brazil and the Latin American territory for a total 32 countries worldwide.

Read the rest here:
TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the ... - PR Newswire (press release)

Puma Biotechnology Inc (PBYI) Breaks into New 52-Week High on May 30 Session – Equities.com

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Shares of Puma Biotechnology Inc (PBYI) broke into a new 52-week high yesterday, hitting a peak of $80.20. Shares closed at $76.90 after opening at $80.15 for a move of -3.57%. The company now has a market cap of $2.84 billion.

Investors and traders can learn a lot about a stocks momentum when it sets a new 52-week high. As an example, bullish investors view a company hitting its highest price in a year as a sign of momentum and may interpret it as a signal to buy. On the other hand, bearish investors could view a new 52-week high as a signal of the end of a strong run, with the stock possibly peaking out before an impending period of decline.

For Puma Biotechnology Inc, the new 52-week high came on volume of 1.52 million. The stock has a float of 36.97 million shares and average daily volume of $1.37 million. It has a 50-day SMA of $40.01 and a 200-day SMA of $43.35.

For a complete fundamental analysis analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.

What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow Jones Industrial Average or S&P 500.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

More:
Puma Biotechnology Inc (PBYI) Breaks into New 52-Week High on May 30 Session - Equities.com

JPMorgan Chase & Co. Acquires 245458 Shares of iShares NASDAQ Biotechnology Index (IBB) – The Cerbat Gem


The Cerbat Gem
JPMorgan Chase & Co. Acquires 245458 Shares of iShares NASDAQ Biotechnology Index (IBB)
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo JPMorgan Chase & Co. raised its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 45.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional ...
iShares NASDAQ Biotechnology Index (IBB) Receiving Somewhat Favorable Media Coverage, Analysis ShowsSports Perspectives
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Folger Nolan Fleming Douglas Capital Management Inc.Chaffey Breeze
The Ameriprise Financial Inc. Increases Stake in iShares NASDAQ Biotechnology Index (IBB)BangaloreWeekly

all 10 news articles »

Read more from the original source:
JPMorgan Chase & Co. Acquires 245458 Shares of iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

‘Young Sheldon’, ‘Grey’s Anatomy’ Spinoff Among 13 U.S. Series Picked Up By CTV LA Screenings – Deadline

Canadian broadcast network CTV has picked up four new U.S. comedies and nine dramas from this years Los Angeles Screenings for the 2017-18 season.

They are comedies The Big Bang Theory spinoff Young Sheldon, Me, Myself & I from CBSandRoseanne revival and The Mayor from ABC. Dramas include Shondalands untitled Greys Anatomy spinoff, which will premiere midseason, and new legal drama For the People. Also on the list are new ABC dramas The Good Doctor, Ten Days in the Valley, The Crossing, Deception, The Gospel of Kevin and Marvels Inhumansalong with Foxs The Gifted.

CTV and CTV Twos 2017-18 primetime schedules will be unveiled at the CTV Upfront on June 7 in Toronto.

CTVs strategically curated mix of the years most-buzzed about sitcoms and compelling dramas sets the stage for viewers to root for both heroes, families and even misfits with heart, said Mike Cosentino, SVP Content and Programming atCTV parent company Bell Media. We cant wait to share our powerful new slate with advertisers and viewers next week.

More:
'Young Sheldon', 'Grey's Anatomy' Spinoff Among 13 U.S. Series Picked Up By CTV LA Screenings - Deadline

Anatomy and physiology of ageing 5: the nervous system – Nursing Times

Download a print-friendly PDF file of this article here

John Knight is senior lecturer in biomedical science; Yamni Nigam is associate professor in biomedical science, both at the College of Human Health and Science, Swansea University.

The nervous system controls the activities of all body organs and tissues, receiving input from sensory organs and responding via effector organs. With around 100billion interconnected neurons, the brain is an extremely complex, and still poorly understood, organ. However we do understand, to some degree, how age affects it, as well as the nervous system as a whole. This fifth article in our series on the anatomy and physiology of ageing describes the age-related changes occurring in the brain, spinal cord and peripheral nerves. These changes lead to a gradual decline in cognitive function and a range of other issues, such as reduced bladder control or postural hypotension, but in health the brain normally continues to function adequately throughout life.

Knight J, Nigam Y (2017) Anatomy and physiology of ageing 5: the nervous system. Nursing Times [online]; 113: 6, 55-58.

The nervous system, along with the endocrine system, controls and integrates the activities of all the bodys organs and tissues. It receives and processes sensory input from organs such as the eyes, ears and skin, and responds through a variety of effector organs.

The main organ of the nervous system is the brain, which, with around 100billion interconnected neurons, is extremely complex; despite decades of research, its function remains poorly understood. Ageing leads to a progressive loss of neurons and depletion of neurotransmitters (Mather, 2016), these changes are usually associated with a gradual decline in cognitive function and influenced by environmental, genetic and lifestyle factors (Nyberg et al, 2012).

The ageing brain gradually loses neurons and supporting neuroglial cells (Fig 1). Between the ages of 20 and 60, the brain loses around 0.1% of neurons per year, after which the process speeds up (Esiri, 2007). By the age of 90, brain mass will have decreased by around 11% compared with individuals in their 50s, which equates to a loss of about 150g of neural tissue (Wyss-Coray, 2016). The remaining tissues harbour an increased concentration of potentially harmful materials such as iron, aluminium and free radicals.

Aged neural tissues also show increasing pigmentation, largely due to the deposition of two pigments: one brown, lipofuscin (Ottis et al, 2012), and one black, neuromelanin (Clewett et al, 2016). Lipofuscin is linked to amyloid

protein deposition and the formation of neurofibrillary tangles. These abnormal areas of neural tissue are often present at low densities in aged brain tissue, even in the absence of disease (Wyss-Coray, 2016); however, where Alzheimers disease is present, these are at high densities.

The loss of neurons is most apparent in the cerebral cortex. The grooves (sulci) that mark the surface convolutions (gyri) of the cerebral cortex are visibly deeper in brains of older people (Fig 1). It was originally thought that the frontal lobes were particularly vulnerable to neural loss, but similar losses have been observed in other cortical regions such as the parietal lobes (Fjell et al, 2014).

Fig 1. Three age-related changes in the brain

Fig 1. Three age-related changes in the brain

Structural changes in the frontal and parietal lobes are related to poor memory. Many people in their 80s have modest levels of amyloid protein deposition and retain their memory, while individuals with higher levels typically have a poorer working (short-term) memory (Nyberg et al, 2012). However, the role of amyloid deposition in impairing memory has recently been questioned and other factors, such as accumulation of tau proteins, may play a more important role (Brier et al, 2016).

The hippocampus has a key role in memory and the acquisition of new skills. With age, it loses a significant amount of neural tissue (Burke and Barns, 2006), which may explain why activities such as learning a new language become more difficult with advancing age. Recent research indicated that navigating a computer-generated virtual environment improved spatial awareness and reduced the shrinkage of the hippocampus, both in younger and older people (Lvdn et al, 2012). Virtual reality computer programs could therefore potentially be used to reduce shrinkage in this vital brain area.

Around 35% of people over the age of 70years have gait problems; while there are many contributing factors, including age-related changes to muscles and joints, the nervous system is also implicated. The somatic motor cortex located in the frontal lobes of the brain controls the movement of muscles involved in walking. From middle age onwards the neurons in this region show signs of atrophy (Manini et al, 2013), which can contribute to gait problems, potentially reducing mobility in older people (Rosso et al, 2013).

Ageing is associated with a gradual increase in the size of the ventricles (fluid-filled chambers) in the brain (Fig 1). This is likely to result from a progressive loss of the cells that line the ventricles. Enlarged ventricles fill with more cerebrospinal fluid, and are readily observable using techniques such as magnetic resonance imaging. On average, the volume of the ventricular system increases by around 2.9% per year; this expansion appears to accelerate with age, with people over the age of 70 having a median rate of expansion of 4.25% per year (Raz and Rodrigue, 2006). Although ventricular expansion is seen in most older people, the cognitive impact of this remains unclear.

The medulla oblongata and other areas of the brainstem lose fewer neurons than other regions of the brain. The brainstem is probably the best preserved region of the brain, which probably reflects its essential role in supporting life: it controls breathing, peristalsis, heart rate and blood pressure. However, the autonomic function of the brain does decline with age and this can compromise the bodys ability to respond quickly to internal and external environmental changes (Hotta and Uchida, 2010). Both branches of the autonomic nervous system (ANS) the parasympathetic and sympathetic branches are compromised with age (Parashar et al, 2016).

These changes can negatively affect older people. For example, the blunting of baroreceptor responses increases the risk of postural hypotension, so standing up suddenly can lead to falls and injury. Another negative consequence is the gradual loss of bladder control. To control micturition, the body relies on the interplay of sensory stretch receptors and the ANS (which together monitor bladder filling) and the conscious areas of the cerebral cortex (which signals when the bladder is full). To initiate micturition, the body needs motor control of the urinary sphincter. All these elements function less well with age, and these age-related changes combine with those in other body systems such as prostate enlargement in men and weakened pelvic floor muscles in women to reduce bladder sensitivity and control (Hotta and Uchida, 2010), which can lead to continence problems.

Cerebral blood flow decreases by around 0.38% per year, equating to a 27% decline over 70years of life (Chen et al, 2011). This is a direct consequence of the age-related changes in the cardiovascular system, and may be exacerbated in patients with atherosclerotic occlusion of the carotid arteries.

The blood-brain barrier (BBB) is formed primarily of tight junctions between adjacent endothelial cells within the blood vessels in the brain. Additionally, specialised neuroglial cells called astrocytes wrap around the cerebral vessels, forming a further physical barrier between the blood and neural tissues. The BBB is essential to prevent most pathogens and many toxic materials crossing into the neural networks and pathways of the brain, but its integrity appears to diminish with ag
e. A recent study indicates that, during normal ageing, the BBB is first weakened in the hippocampus, thereby allowing harmful substances and pro-inflammatory mediators to cross into this vital region of learning and memory. This breaching of the BBB may contribute to hippocampal shrinkage, and therefore to cognitive decline (Montagne et al, 2015).

Ageing is associated with a declining production of many neurotransmitters, including noradrenaline, glutamate, dopamine and serotonin. The decline in dopamine appears to be particularly important: dopamine modulates motor function and the acquisition of new skills, while also acting as one of the brains reward chemicals (Mather, 2016). The number of dopamine-producing neurons decreases as part of the normal ageing process, and this can adversely affect the ability to learn from past experiences. Recent studies show that many older people who boosted their levels of dopamine by taking L-DOPA (a drug normally used to treat Parkinsons disease) were learning as quickly as young adults again (Chowdhury et al, 2013).

Few studies have examined age-related changes to the spinal cord. A recent animal-model study shows an increase of cholesterol content in the ageing spinal cord, and the authors suggest this may potentially impair cord function (Parkinson et al, 2016).

Age-related changes to neurons and neuroglial cells appear to have little effect on spinal cord function. However, age-related changes to the vertebrae and intervertebral discs may increase pressure on the spinal cord and its branching nerve roots. This can slow down the conduction of nerve impulses along motor neurons, contributing to reduced muscular strength (Manini et al, 2013). Reduced sensory and motor conduction will increase the risk of injury due to poor coordination, poor balance and poor fine motor control.

With age, some peripheral neurons show a dying back (shrinkage of axonal length), loss of mitochondria and a degeneration of their insulatory myelin sheaths. Some of this damage may be caused by a rise in the concentrations of pro-inflammatory mediators in the body. The ageing body becomes less effective in clearing toxic metabolites and, as peripheral nerves are not afforded the protection of the BBB, this may contribute to peripheral nerve damage (Manini et al, 2013).

The loss of myelin slows the conduction of peripheral nerve impulses by around 5-10% (Joynt, 2000). In health, this reduction in conductivity causes few problems, but in older people with diabetes it may contribute to, and exacerbate, diabetic neuropathy. Damaged peripheral nerves are not repaired as efficiently in older people as in their younger counterparts, and some of these nerves are never repaired. This can contribute to reduced sensation and motor control.

In the absence of disease, intellectual ability can be retained throughout life. However, the gradual loss of neurons, depletion of neurotransmitters and slowing of nerve conduction may act together to slow down the processing of information. As a result, older people may take longer to complete certain tasks, and commonly experience the functional brain changes described below.

The loss of short-term and episodic memory is probably the earliest indication of age-related changes in the brain. Unlike what happens in dementia, the loss of short-term memory in the absence of disease does not affect life skills (such asthe ability to cook), but manifests as inconveniences (such as forgetting an item from the shopping list). Episodic memory (that is, remembering autobiographical events and their timings and sequence) also gradually declines in many older people (Fjell et al, 2014).

Verbal communication skills generally remain strong throughout life (Park and Reuter-Lorenz, 2009), but people over the age of 70years may have increasing problems using or recalling words. The ability to quickly name a common object usually remains stable up to the age of 70, but then declines with advancing years (Harada et al, 2013).

The progressive loss of neurons, reduction in impulse velocity and minor changes in the spinal cord lead to a slowing down of reaction times (Spirduso, 1995). This can create problems, particularly when a fast reaction is essential (for example, to step out of the way of oncoming traffic).

In England, around 22% of men and 28% of women over the age of 65 are affected by depression; in care homes, the figures are even greater, with around 40% of residents affected (Age UK, 2017).

It is almost impossible to determine whether depression in older people occurs as a normal consequence of ageing or as a result of chemical imbalances seen in types of depression that also affect younger people. Concentrations of neurotransmitters involved in lifting mood (particularly serotonin) diminish with age and this can contribute to symptoms of depression (Fidalgo et al, 2013). The Royal College of Psychiatrists estimates that >85% of depressed older people receive no help from the NHS (Age UK, 2017). Depression can often produce symptoms that mimic dementia (pseudo-dementia) and this often causes great anxiety.

On the whole, older people are less prone to emotional outbursts than younger people. This may be related to the relative structural stability of some of the brain regions linked to emotions. Most studies of the amygdalae which are heavily involved in impulsive behaviours and emotional reactions reveal little evidence of atrophy or shrinkage at a much slower rate than in other brain regions. Additionally, the amygdalae also appear to retain most of their functional activity in older age (Mather, 2016).

Because the overall neural mass reduces with age, neuroactive drugs such as antidepressants and neuroleptics can be more potent in older people. Doses normally prescribed to adults may induce confusion or delirium, and may therefore need to be adjusted.

How normal age-related changes to the brain can be distinguished from pathological changes associated with dementia (for example, Alzheimers disease) is hotly debated. The problem is that three of the main clinical features of Alzheimers disease loss of episodic memory, loss of brain tissue and amyloid deposition are also seen in apparently healthy older people with little or no evidence of dementia. However, it is generally recognised that the main risk factor for developing dementia is advancing age (Fjell et al, 2014).

Unlike cells in many other parts of the human body, most neurons do not undergo cell division so, when they dieas a result of age or injury, they are generally not replaced. Fortunately, the brain contains over 100billion interconnected neurons (the connectome) and many researchers agree that it has an in-built redundancy, known as the brain reserve. This is defined as the physical resources of the brain in terms of brain mass and number of neurons; a larger brain reserve is often associated with better outcomes after brain injury and in various neurological diseases (Tucker and Stern, 2011).

The brain reserve is not necessarily a good predictor of cognitive function (many people with normal cognition have significant brain atrophy), so the concept of cognitive reserve has emerged. People with a high cognitive reserve are able to use their brain reserve more efficiently to perform tasks, and this seems to happen through increased efficiency of functional connections between neurons (Marques et al, 2016).

Good predictors of a high cognitive reserve include high education level, high IQ, highly complex occupation and large amount of social interaction. Recent research indicates that cognitive ability may also be maintained by neural compensation, a process in which new circuits of neurons are recruited to perform tasks that were once carried out by aged ordamaged neural pathways (Steffener and Stern, 2012). In normal ageing, the brain reserve does decline but cognition ismaintained thanks to the brains in-built redundancy.

Keeping mentally active throughout life can reduce the effects of age on th
e nervous system (Mahncke et al, 2006), and engaging in social, sporting and mentally challenging activities can slow downthe decline in cognitive performance (Nyberg et al, 2012). It appears the more intellectually demanding and complex an individuals occupation, the better their cognitive performance in later years; however, in retirement, when the mental challenges of work are removed, this effect appears to decline.

Older people should be encouraged to engage in stimulating activities such as socialising, reading and games, which are thought to improve cognitive function and memory, as well as reduce the riskof depression. It is a common misconception that ageing naturally leads to conditions such as confusion, dementia and delirium. The human brains in-built redundancy allows it to adequately cope with the physical changes associated with ageing. Indeed, in the absence of disease, adequate mental function can be retained throughout life.

Age UK (2017)Later Life in the United Kingdom, January 2017.London: Age UK.

Brier MR et al (2016) Tau and A imaging, CSF measures, and cognition in Alzheimers disease.Science Translational Medicine;8: 338, 338ra66.

Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain.Nature Reviews Neuroscience;7: 1, 30-40.

Chen JJ et al (2011) Age-associated reductions in cerebral blood flow are independent from regional atrophy.Neuroimage;55: 2, 468-478.

Chowdhury R et al (2013) Dopamine restores reward prediction errors in old age.Nature Neuroscience;16: 5, 648-653.

Clewett DV et al (2016) Neuromelanin marks the spot: identifying a locus coeruleus biomarker of cognitive reserve in healthy aging. Neurobiology of Aging; 37: 117-126.

Esiri MM (2007) Ageing and the brain. Journal of Pathology; 211: 2, 181-187.

Fidalgo S et al (2013) Serotonin: from top to bottom. Biogerontology; 14: 1, 21-45.

Fjell AM et al (2014) What is normal in normal aging? Effects of aging, amyloid and Alzheimers disease on the cerebral cortex and the hippocampus. Progress in Neurobiology; 117: 20-40.

Harada CN et al (2013) Normal cognitive aging; Clinics in Geriatric Medicine; 29: 4, 737-752.

Hotta H, Uchida S (2010) Aging of the autonomic nervous system and possible improvements in autonomic activity using somatic afferent stimulation. Geriatrics and Gerontology International; 10: Suppl 1, S127-S136.

Joynt RJ (2000) Aging and the nervous system. In: The Merck Manual of Geriatrics. West Point PA: Merck & Co.

Lvdn M et al (2012) Spatial navigation training protects the hippocampus against age-related changes during early and late adulthood. Neurobiology of Aging; 33: 3, 620.e9-620.e22.

Mahncke HW et al (2006) Memory enhancement in healthy older adults using a brain plasticity-based training program: a randomized, controlled study. Proceedings of the National Academy of Sciences of the United States of America; 103: 33, 12523-12528.

Manini TM et al (2013) Aging and muscle: a neurons perspective. Current Opinion in Clinical Nutrition and Metabolic Care; 16: 1, 21-26.

Marques P et al (2016) The functional connectome of cognitive reserve. Human Brain Mapping; 37: 9, 3310-3322.

Mather M (2016) The affective neuroscience of aging. Annual Review of Psychology; 67: 213-238.

Montagne A et al (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron; 85: 2, 296-302.

Nyberg L et al (2012) Memory aging and brain maintenance. Trends in Cognitive Sciences; 16: 5, 292-305.

Ottis P et al (2012) Human and rat brainlipofuscin proteome. Proteomics; 12: 15-16, 2445-2454.

Parashar R et al (2016) Age related changes in autonomic functions. Journal of Clinical and Diagnostic Research; 10: 3, CC11-CC15.

Park DC, Reuter-Lorenz P (2009) The adaptive brain: aging and neurocognitive scaffolding. Annual Review of Psychology; 60: 173-196.

Parkinson GM et al (2016) Perturbed cholesterol homeostasis in aging spinal cord. Neurobiology of Aging; 45: 123-135.

Raz N, Rodrigue KM (2006) Differential aging of the brain: patterns, cognitive correlates and modifiers. Neuroscience and Biobehavioral Reviews; 30: 6, 730-748.

Rosso AL et al (2013) Aging, the central nervous system, and mobility. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences; 68: 11, 1379-1386.

Spirduso WW (1995) Physical Dimensions of Aging. Champaign, Il: Human Kinetics.

Steffener J, Stern Y (2012) Exploring the neural basis of cognitive reserve in aging. Biochimica et Biophysica Acta; 1822: 3, 467-473.

Tucker AM, Stern Y (2011) Cognitive reserve in aging. Current Alzheimer Research; 8: 4, 354-360.

Wyss-Coray T (2016) Ageing, neurodegeneration and brain rejuvenation. Nature; 539: 7628, 180-186.

More:
Anatomy and physiology of ageing 5: the nervous system - Nursing Times

Global Market Study on Biochemistry Analyzers: Clinical Diagnostics Application Segment Projected to Retain Its … – PR Newswire (press release)

LONDON, May 29, 2017 /PRNewswire/ -- About the Report

Persistence Market Research in its latest report titled 'Biochemistry Analyzers Market: Global Industry Analysis and Forecast, 2016-2024' has presented a comprehensive research on the competition landscape in the global biochemistry analyzers market. The competition landscape portion of the global biochemistry analyzers market report begins by introducing the readers of the report to the company share analysis of all the important players operating in the global biochemistry analyzers market. This section of the report gives the breakup of the market share of all the key players operating in the global biochemistry analyzers market and observes that the market is highly fragmented owing to the presence of various companies, especially domestic players, in the global biochemistry analyzers market. In the subsequent section of the report, a competition dashboard is presented, which supplies information on various key players operating in the global biochemistry analyzers market; such as product offerings, regional presence and most important of all, strategies adopted by the key market players in order to succeed in the global biochemistry analyzers market. This kind of information is important for any new entrants or established players operating in the global biochemistry analyzers market as it provides insights on the kind of strategies being adopted by the leading market players so that they can emulate their success and also gauge the effectiveness of such strategies in different regions of the global biochemistry analyzers market.

Download the full report: https://www.reportbuyer.com/product/4921067/

In the subsequent sections of the competition landscape, individual information is supplied on the various key players operating in the global biochemistry analyzers market. The kind of information that is given includes company details, company description, product offerings, key financial information and key developments pertaining to the company. In addition, a strategic overview of the companies is also given that provides valuable information regarding the direction that the company is taking with respect to the market in the coming few years and how this will impact the global biochemistry analyzers market. Last but not the least, a SWOT analysis of all the key market players is also given in the competition landscape that provides deep insights regarding the key market players operating in the global biochemistry analyzers market and how the key market players are going to shape up the global market in the future with regards to their strengths and weaknesses and how they utilize the opportunities provided to them and tackle the various market threats and challenges.

Besides this, in the beginning of the report, a market forecast is given that comprises three scenarios, namely the conservative scenario, the likely scenario and the optimistic scenario. All of these three scenarios will result in different market numbers and growth rates and the report gives information why a particular scenario has been chosen as the most likely scenario in the global biochemistry analyzers market and also gives information regarding the other scenarios that may change the market forecasts, if at all, and the magnitude of the change on the forecasted market numbers and growth rates. Besides this, a section on regional biochemistry analyzers market volume (Unit Mn) analysis and forecast by product type, 2016-2024 is also given that provides an overview of the volume share in the regional biochemistry analyzers market and which region is the largest, most lucrative and fastest growing in terms of volume so that correct decisions pertaining to the global biochemistry analyzers market are taken. In addition, there is a section of the report devoted to the fully and semi-automated biochemistry analyzers price forecast by region, 2015 & 2024. This section of the report gives a price overview of the market region wise, so that important decisions on market growth and expansion can be taken by the players who wish to operate in the biochemistry analyzers market.

Another important and attractive feature of the global biochemistry analyzers report present by Persistence Market Research is the inclusion of PEST analysis. The detailed PEST analysis provided in the report gives all the important political, economic, social and technological aspects governing the global biochemistry analyzers market so that readers are fully aware of all the important factors that directly or indirectly affect the growth of the biochemistry analyzers market globally. Besides, information about the Laboratory Accreditation: Internal Quality Control (IQC), Laboratory Accreditation: External Quality Assessment Scheme (EQAS) are also given, adding more value to the report. Important guidelines by the Clinical and Laboratory Standards Institute (CLSI) are provided to enable readers to get an idea about the nuances of the global biochemistry analyzers market.

Also, in addition to all the above, the biochemistry analyzers market report contains an executive summary and also market definitions and the market taxonomy. Macroeconomic factors affecting the global biochemistry analyzers market along with the demand side drivers and supply side drivers are also given in order to give a deep overview of the global biochemistry analyzers market. Besides, restraints impacting the market along with opportunities and trends shaping up the biochemistry analyzers market also given to further add value to the report. The global biochemistry analyzers market analysis and forecast by product type, by end user, by modality, and by region is also given. This section of the report contains valuable information like Basis Point Share (BPS) analysis, Y-o-Y growth projections and market attractiveness analysis to provide in-depth insights into the global biochemistry analyzers market.

Market Segmentation

By Product Type

Semi-automated Biochemistry Analyzer Fully Automated Biochemistry Analyzer

By Application

Clinical Diagnostics Bioreactor Byproduct Detection Drug Development Applications Others

By Modality

Bench-top Floor standing

By End User

Hospitals Diagnostic Centers Pharmaceutical Companies Biotechnology Companies Academic Research Institutes Contract Research Organizations Academic Research Institutes

By Region

North America Latin America Europe Asia Pacific Download the full report: https://www.reportbuyer.com/product/4921067/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-market-study-on-biochemistry-analyzers-clinical-diagnostics-application-segment-projected-to-retain-its-dominance-through-2024-300465065.html

SOURCE ReportBuyer

http://www.reportbuyer.com

Read more:
Global Market Study on Biochemistry Analyzers: Clinical Diagnostics Application Segment Projected to Retain Its ... - PR Newswire (press release)

Anatomy of a Goal: Morrow Makes it 2 – Massive Report

Welcome to the Anatomy of a Goal, where each week we dissect one goal (or near goal) from Columbus Crew SCs previous match.

For match 14 of the 2017 MLS Season, we take a look at Toronto FC midfielder Justin Morrows 39th minute goal that put Toronto up 2-0 as part of the 5-0 win over Crew SC on Friday.

Heres a look at the finish from the Toronto FC midfielder.

It was hard to pick just one of Torontos five goals to break down, but Morrows goal is indicative of Torontos successful strategy in this match. When Columbus pushed up the field, Toronto looked to counter quickly, often playing a long pass into the Crew SC defense, looking to build off of a turnover or a win of possession by TFC.

During the first half, Crew SC lined up in what the official lineup called a 4-4-2, with Wil Trapp and Federico Higuain playing together in the midfield. This 4-4-2 sacrificed a defensive midfielder for an attacker, and left Trapp with much more ground to cover. As the lone defensive midfielder, Trapp was often the only player in the middle of the field, leaving acres of space for Toronto runners and creating chaos for the Crew SC defense.

Morrows goal begins with this Kekuta Manneh clearance. Manneh, lined up at forward, stuck to the left side of the field for much of the match. Here, Manneh has tracked back on defense, and seeing no other options, clears the ball up the field.

TFC center-back Eriq Zavaleta, pressured by Ola Kamara, heads the ball forward into the path of Michael Bradley.

Bradley immediately plays a risky pass back to Zavaleta, who is directed to clear the ball by fellow center-back Drew Moor. Notice here that Crew SC has 4 players in Toronto FCs defensive half. Wil Trapps midfield partner, Federico Higuain, provides the most pressure to Zavaletas clearance. By providing this pressure, Higuain leaves Trapp alone to cover much of the midfield.

Once Zavaleta clears the ball forward, Toronto immediately has a numerical advantage over Crew SC. Wil Trapp, highlighted near midfield, is almost totally alone in the midfield, because Higuain was pressuring the TFC center-backs. Jonathan Mensah is back the furthest on defense. Nicolai Naess is marking TFC striker Ben Spencer, while Harrison Afful doesnt seem to realize that Justin Morrow is totally unmarked right behind him.

As Waylon Francis receives the ball, he has two options: get the ball to Trapp, alone in the middle of the field, or send the ball up the sideline/out of bounds.

Francis opts to send the ball toward Trapp, but note the way the he heads the ball. Francis heads the ball with his momentum going away from the ball. Because his momentum is away from the ball, Francis slows the ball down, sending an incredibly weak and slow pass toward Trapp, who has to speed up to receive the ball.

Ben Spencer notices the weak pass, and immediately heads toward the ball.

Trapp and Spencer are in a footrace to the ball while the Crew SC defense drops into shape. Notice that Harrison Afful, just above the highlighted Ben Spender, is still unaware of Justin Morrow.

Trapp appears to be on track to win the ball, but has Ben Spencer bearing down on him. To make a successful pass, Trap would have to immediately play a first touch pass to one of the three Crew SC players near him: Nico Naess, Jonathan Mensah, or Waylon Francis.

However, as the above video shows, the ball takes a high bounce right before it gets to Trapp, and the Crew SC midfielder is unable to play a first touch pass. Forced to take an awkward touch on the ball, Trapp is dispossessed by the much larger Ben Spencer. Trapp is listed at 58 and Spencer is listed at 65 and Spencer easily knocks Trapp off the ball to spring the Toronto attack.

Having just dispossessed Trapp, Spencer has two options. Because Naess has shifted to cover him, Spencer will have to make a pass: a slotted ball to Tosaint Ricketts, who would be marked by Jonathan Mensah, or an easy pass to Justin Morrow, who is running at pace and will be just ahead of Harrison Afful. To Affuls credit, he finally noticed Morrow sprinting behind him, but will start his run too late to catch the TFC midfielder.

With Afful having pushed high up the field, notice now much space is open on the Crew SC defensive right flank.

Spencer opts to push the ball to the onrushing Morrow, who has already pushed ahead of Harrison Afful. As has happened a few times this year, Afful is forced to catch up with a midfielder who has built up pace while Afful was pushed up the field. This isnt necessarily Affuls fault, but the Crew SC right back, and the Crew SC managerial staff, have to realize that teams have punished Afful being pushed too far upfield multiple times this season. When Afful pushes that far up field, he does not have the luxury of being able to mentally switch off, and must be aware of his surroundings at all times. Afful was absolutely switched off until he noticed Morrow streaking over his left shoulder.

As Morrow approaches the ball, Afful catches up to him. If Afful can get in front of Morrow, he can force the TFC midfielder to take a difficult shot or make a cross to one of the, well-defended, TFC players in the box.

As Morrow prepares to shoot or pass, notice the Crew SC defense. For some reason, Naess has totally abandoned Ben Spencer, the tallest player on the field, who is now making an undefended run into the box. Naess may be attempting to get in front of Morrow, but the TFC midfielder already has a difficult angle on goal. Naess should have stayed with Spencer in an attempt to prevent TFCs tall striker from being open for a chipped cross.

But, Naesss leaving Spencer doesnt matter. Morrow fires a left-footed rocket at the near post. Afful has recovered, and does a good job to cut off Morrows crossing angles, forcing that shot from a tough angle. Afful should expect his goal keeper to have the near post covered from that angle.

However, Zack Steffen is caught flat-footed and is beaten to his near post by Morrows shot. Morrows shot here is excellent and perfectly placed, but Steffen cannot afford to be beaten to his near post from that angle.

Findings:

Read more from the original source:
Anatomy of a Goal: Morrow Makes it 2 - Massive Report

Aesthetic Medicine: 5 top trends at the AMWC – Premium beauty

Skin-quality injections

All the big players have always had this kind of shallow micro-injection on the surface of the skin. Previously we called them Skin Boosters but they were underdeveloped and the focus was more on Hydration. It was positioned as an alternative to Mesotherapy (NCTF Filorga).

Today, studies show that skin quality isnt being addressed as much as it could be in doctors clinics. Many patients complain about Skin Fatigue the words being used by patients are: less radiant, dull, tired, dry and exhausted.

A newcomer was launched at the show by Allergan - Juvderm Volite - to treat skin quality; an HA (Hyaluronic-acid injection) to add smoothness, hydration and elasticity. Results last for 9 months.

Read more: http://www.allergan.com

Aesthetic medicine can be divided in 2 types of treatments:

The future is having both in one treatment: corrective & regenerative.

The use of autologous treatment such as PRP is being adopted in many clinics. Its largely used in medicine to treat sport injuries, arthritis and surgical wounds. Its an easy treatment to perform. The treatment uses the patients own blood. During a simple centrifuge process, the platelets and fibrins will be isolated from the blood. The resulting product (a liquid gel) is re-injected in the skin. The entire process takes 15-20 minutes. The difference between HA and this treatment for volume restoration is that the idea is not to fill the wrinkles but to stimulate the fibroblasts and the growth factors which will produce new collagen to regenerate the dermis, restore hydration and renew the skin.

There is a new treatment to treat the double-chin; even though doctors prefer to use the term submental fullness (double-chin makes patient feel like they are overweight).

Kybella (first launched in the US in 2016) is called Belkyra in Europe (it has just been launched in 2017). Kybella / Belkyra are a chin-fat reducing injections. The fat melting injection forsub-mental (under the chin) fat was approved by the FDA in April 2015. Its made from deoxycholic acid - a naturally occurring molecule, used by the body to rid unwanted fat. It breaks down the cell walls of fatty tissue. The body can then safely eliminate the unwanted tissue. As fat cells die off, they do not return. It has mainly been used to treat double chins but will be used for buttocks, neck and arms. It hurts, causes inflammation, but works. Results occur at 12 weeks. The treatment is popular amongst both men and women

Lifting threads as an alternative to facelifts are getting really popular in doctors offices. Redefining the face, restoring volume and reducing wrinkles are what the latest threads treatment can achieve. The lifting effect is immediate and discreet as it is the result of compressing the tissue and elevating the skin at the time of implanting the suture.

There is also a tissue stimulation effect with threads that comes from for example:

Universkin is a French cosmeceuticals brand with a mission to revolutionize the cosmeceuticals industry by challenging an obsolete cosmetics market and providing on-the-spot bespoke skincare.

Whats the concept?

The doctor will assess your skin care concerns based on a questionnaire which then colour codes the outcome to match specific ingredients. A tailor-made serum called Nexultra P will be created. All the three specific bespoke actives come in a powder form and are mixed in the serum base with a centrifuge-type machine.

The choice of three specific compounds following the patients exact skin needs:

The product includes only fresh actives and no preservatives, therefore it has a shelf-life of 6 weeks. It must be put into the fridge if the product hasnt been finished after 6 weeks. To learn more: http://www.universkin.com

Read more:
Aesthetic Medicine: 5 top trends at the AMWC - Premium beauty

Biochemistry Conferences | Global Events | Meetings | USA …

TheBiochemistry conferencesdeals with the most recent research on structures, functions and interactions of biologicalmacromolecules, such asproteins,nucleic acids,carbohydratesandlipids, which provide the structure of cells and perform many of the functions associated with life. TheBiochemistry conferencesbring together researchers from multiple scientific disciplines, primarily from the field of medicine, nutrition, and agriculture to catalyse new discoveries and shape future research. In medicine, biochemists investigate the causes and cures of disease. In nutrition, they study how to maintain health and study the effects of nutritional deficiencies. In agriculture, biochemists investigate soil and fertilizers, and try to discover ways to improve crop cultivation, crop storage and pest control.

Conference Series Conference Seriesthrough its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. Conference Series hosts over 700+ leading-edgepeer reviewed Open Access journalsand has organizing over 1000+Global Eventsall over the world. Biochemistry conferenceshost presentations from experts across the world in the field of Life Sciences. These Biochemistry conferences are of main interest to the scientists and professors working in the field of Bioinformatics, Proteomics, Metabolomics, Transcriptomics, Structural Biology, Next Generation Sequencing, Glycobiology, Lipid Science, Genetic and Protein Engineering, Glycomics, Amino Acids and Proteins and Computational System biology.

Bioinformaticshost presentations based on tools and techniques which are used to explore the Protein sequences.Proteomicsdeals with the conferences describing the structure, functions and interactions of proteins. The field ofMetabolomicsincludes conferences based on the study of small-molecule metabolites such as metabolic intermediates, hormones and other signaling molecules, and secondary metabolites.Transcriptomicsincludes presentation based on the study of complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell using high-throughput methods, such as microarray analysis.Structural Biologyholds the conferences to discuss the molecular structure of biological macromolecules, especially proteins and nucleic acids, how they acquire the structures they have, and how alterations in their structures affect their function.Next Generation Sequencingapplies to genome sequencing, transcriptome profiling (RNA-Seq), DNA-protein interactions (ChIP-sequencing), and epigenome characterizationGlycobiologypresent the talks on the study of the structure, biosynthesis, and biology ofsaccharides that are widely distributed in nature.Lipid Scienceenhances the knowledge and understanding of the lipid metabolism and associated disorders, lipid-protein interactions, lipid biosynthetic enzymes and transport proteins, and the regulation of the genes involving in metabolic diseases.Genetic and Protein Engineeringthrow light on how in Genetic engineering, the direct manipulation of an organism's genome occur using biotechnology and how the useful or valuable proteins are developed using Protein engineering. Glycomics, a new topic containing talks on the study ofglycomes(the entire complement ofsugars, whether free or present in more complexmoleculesof anorganism), including genetic, physiologic, pathologic, and other aspects.Amino Acidsand Proteinscomprise discussion on the synthesis, structure, function and purification of these molecules.Computational Systems Biologyembraces computational modelling in response to the quantitative nature and increasing scale of contemporary datasets.

All of ourBiochemistry conferencestake place in two-three days. During the conference major sessions like speaker sessions and poster presentation, young research forum are organized. Special sessions like International symposium, workshop are also the part of the conference.

Student Poster Competition is organized at Conferences, to encourage students and recent graduates to present their original research which will be later published in the International Journals. All accepted abstracts will be presented at the poster sessions during the conference. Conference Series LLC provides an opportunity to present e-Poster for all the students who cannot attend the conference at 99$ with abstract published in the website with DOI number Live Streaming is a value added service offering to speaker at our conferences

Business networking is an avenue for vendors to have network with Top scientists and colleagues and with an effective low cost marketing method for developing sales and opportunities and contacts, based on referrals and introductions either face-to-face at meetings and gatherings, or by other contact methods such as Telephone, E mail, Digital and Increasingly social and business networking websites.

Scope and Importance: The analysts forecast the GlobalBiochemistryAnalyzers market to grow at a CAGR of 4.50 percent over the period 2012-2016. One of the key factors contributing to this market growth is the advancements in technology. The Global Biochemistry Analyzers market has also been witnessing the increase in technological innovations. However, the negative impact of global recession could pose a challenge to the growth of this market.

The report, the Global Biochemistry Analyzers Market Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Biochemistry Analyzers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one of the major factors driving the growth of the market is the advancement in technology. The increase in automation of biochemistry analyzers is the key advancement in technology for high-throughput analysis of biochemical entities. High-throughput analysis consumes less time and generates results quickly.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Major Companies:

Major Societies for Biochemistry:

Major Conferences:

January 06-08, 2017 Hong Kong

January 16-18, 2017 Shenzhen, China

January 21-23, 2017 Bangkok, Thailand

January 23-24, 2017 Paris, France

February 06-10, 2017 Heidelberg, Germany

February 10-12, 2017 Brisbane, Australia

February 12-14, 2017 Lorne, Australia

February 13-16, 2017 Heidelberg, Germany

February 20-22, 2017 Innsbruck, Germany

February 20-22, 2017 Baltimore, USA

February 21-23, 2017 Porto, Portugal

February 21-24 2017 Carlsbad, USA

February 22-24 2017 Baltimore, USA

February 26-27, 2017 Dubai, UAE

March 12-17 2017 Heidelberg, Germany

March 20-22, 2017 Honolulu, USA

April 03-05, 2017 Brisbane, Australia

April 13-16, 2017 Cyprus

April 24-26, 2017 Kuala Lumpur, Malaysia

April 26-28, 2017 Granada, Spain

May 01-05, 2017 Boston, MA

May 03-06 2017 Heidelberg, Germany

May 17-19 2017 Paris, France

May 25-26, 2017 United Kingdom,London

June 20-23, 2017 Faro, Portugal

June 19-24, 2017 Dubrovnik, Croatia

July 09-13, 2017 County Dublin, Ireland

July 30-August 04, 2017 New Hampshire, USA

August 27-30, 2017 Uppsala, Sweden

Read more:
Biochemistry Conferences | Global Events | Meetings | USA ...

Briarcliff Student Receives Chemistry Award – Patch.com


Patch.com
Briarcliff Student Receives Chemistry Award
Patch.com
From Briarcliff HS: Briarcliff High School senior Lauren Burnette has been honored by the Westchester Chemical Society for Outstanding Scholastic Performance in High School Chemistry. She received the award at the Society's annual awards symposium on ...

Follow this link:
Briarcliff Student Receives Chemistry Award - Patch.com